{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:19:07Z","timestamp":1761005947125,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1053\/j.jvca.2019.07.136","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T06:59:03Z","timestamp":1564729143000},"page":"3476-3485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Case-Based Discussion on the Management of Cryptogenic Stroke and Patent Foramen Ovale in the Patient With a Hypercoagulable Disorder"],"prefix":"10.1053","volume":"33","author":[{"given":"Neal S.","family":"Gerstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey D.","family":"Clegg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel B.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam C.","family":"Fish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Tolstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2019.07.136_bib0001","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002975","article-title":"An approach to working up cases of embolic stroke of undetermined source","volume":"5","author":"Ryoo","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2019.07.136_bib0002","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/hs1201.100209","article-title":"Epidemiology of ischemic stroke subtypes according to TOAST criteria: Incidence, recurrence, and long-term survival in ischemic stroke subtypes: A population-based study","volume":"32","author":"Kolominsky-Rabas","year":"2001","journal-title":"Stroke"},{"key":"10.1053\/j.jvca.2019.07.136_bib0003","article-title":"European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism","author":"Pristipino","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2019.07.136_bib0004","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jacc.2015.12.023","article-title":"Device closure of patent foramen ovale after stroke: Pooled analysis of completed randomized trials","volume":"67","author":"Kent","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.07.136_bib0005","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJMoa011503","article-title":"Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both","volume":"345","author":"Mas","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0006","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2019.07.136_bib0007","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/0961203316688784","article-title":"Stroke in systemic lupus erythematosus and antiphospholipid syndrome: Risk factors, clinical manifestations, neuroimaging, and treatment","volume":"26","author":"de Amorim","year":"2017","journal-title":"Lupus"},{"key":"10.1053\/j.jvca.2019.07.136_bib0008","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00415-012-6613-4","article-title":"Patent foramen ovale and atrial septal aneurysm can cause ischemic stroke in patients with antiphospholipid syndrome","volume":"260","author":"Tanaka","year":"2013","journal-title":"J Neurol"},{"key":"10.1053\/j.jvca.2019.07.136_bib0009","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1191\/0961203303lu391oa","article-title":"Cardiac disease in the antiphospholipid syndrome: Recommendations for treatment. Committee consensus report","volume":"12","author":"Lockshin","year":"2003","journal-title":"Lupus"},{"key":"10.1053\/j.jvca.2019.07.136_bib0010","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1136\/annrheumdis-2014-205663","article-title":"The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: A systematic review","volume":"74","author":"Sciascia","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.jvca.2019.07.136_bib0011","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/0961203309106832","article-title":"The Euro-Phospholipid project: Epidemiology of the antiphospholipid syndrome in Europe","volume":"18","author":"Cervera","year":"2009","journal-title":"Lupus"},{"key":"10.1053\/j.jvca.2019.07.136_bib0012","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0025-6196(12)60336-X","article-title":"Incidence and size of patent foramen ovale during the first 10 decades of life: An autopsy study of 965 normal hearts","volume":"59","author":"Hagen","year":"1984","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.jvca.2019.07.136_bib0013","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0735-1097(01)01427-9","article-title":"Patent foramen ovale: A review of associated conditions and the impact of physiological size","volume":"38","author":"Kerut","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.07.136_bib0014","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMoa1009639","article-title":"Closure or medical therapy for cryptogenic stroke with patent foramen ovale","volume":"366","author":"Furlan","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0015","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa1301440","article-title":"Closure of patent foramen ovale versus medical therapy after cryptogenic stroke","volume":"368","author":"Carroll","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0016","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","article-title":"Percutaneous closure of patent foramen ovale in cryptogenic embolism","volume":"368","author":"Meier","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0017","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1161\/STROKEAHA.117.018561","article-title":"New data support patent foramen ovale closure after stroke","volume":"49","author":"Favilla","year":"2018","journal-title":"Stroke"},{"key":"10.1053\/j.jvca.2019.07.136_bib0018","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.jcin.2013.08.001","article-title":"Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: A systematic review and meta-analysis","volume":"6","author":"Khan","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1053\/j.jvca.2019.07.136_bib0019","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","article-title":"Long-term outcomes of patent foramen ovale closure or medical therapy after stroke","volume":"377","author":"Saver","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke","volume":"377","author":"Mas","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0021","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","article-title":"Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke","volume":"377","author":"Sondergaard","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0022","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jacc.2003.10.030","article-title":"Incidence and clinical course of thrombus formation on atrial septal defect and patent foramen ovale closure devices in 1,000 consecutive patients","volume":"43","author":"Krumsdorf","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.07.136_bib0023","first-page":"123","article-title":"Antiphospholipid antibodies are common in patients referred for percutaneous patent foramen ovale closure","volume":"61","author":"Dodge","year":"2004","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1053\/j.jvca.2019.07.136_bib0024","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2169\/internalmedicine.39.83","article-title":"Patent foramen ovale and \u201ccatastrophic\u201d antiphospholipid syndrome","volume":"39","author":"Okura","year":"2000","journal-title":"Intern Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0025","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00415-004-0431-2","article-title":"Brain infarction associated with antiphospholipid antibody syndrome caused by paradoxical embolism through patent foramen ovale","volume":"251","author":"Ago","year":"2004","journal-title":"J Neurol"},{"key":"10.1053\/j.jvca.2019.07.136_bib0026","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/hrt.60.5.455","article-title":"Intracardiac thrombosis, phospholipid antibodies, and two-chambered right ventricle","volume":"60","author":"Coppock","year":"1988","journal-title":"Br Heart J"},{"key":"10.1053\/j.jvca.2019.07.136_bib0027","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2459\/01.JCM.0000263497.99157.77","article-title":"Patent foramen ovale: The evident paradox between the apparently simple treatment and the really complex pathophysiology","volume":"8","author":"Rigatelli","year":"2007","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1053\/j.jvca.2019.07.136_bib0028","first-page":"122","article-title":"Management of patients with patent foramen ovale and cryptogenic stroke: A collaborative, multidisciplinary, position paper: Executive summary","volume":"82","author":"Pristipino","year":"2013","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1053\/j.jvca.2019.07.136_bib0029","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"10.1053\/j.jvca.2019.07.136_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008356","article-title":"Closure, anticoagulation, or antiplatelet therapy for cryptogenic stroke with patent foramen ovale: Systematic review of randomized trials, sequential meta\u2010analysis, and new insights from the CLOSE Study","volume":"7","author":"Turc","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2019.07.136_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2015.09.011","article-title":"Guidelines for the use of echocardiography in the evaluation of a cardiac source of embolism","volume":"29","author":"Saric","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1053\/j.jvca.2019.07.136_bib0032","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: The case for a new clinical construct","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.jvca.2019.07.136_bib0033","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1212\/WNL.0b013e3182a08d59","article-title":"An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke","volume":"81","author":"Kent","year":"2013","journal-title":"Neurology"},{"key":"10.1053\/j.jvca.2019.07.136_bib0034","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.jacc.2018.02.046","article-title":"Cryptogenic stroke and high-risk patent foramen ovale: The DEFENSE-PFO trial","volume":"71","author":"Lee","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.07.136_bib0035","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.echo.2014.05.011","article-title":"Guidelines for the cardiac sonographer in the performance of contrast echocardiography: A focused update from the American Society of Echocardiography","volume":"27","author":"Porter","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1053\/j.jvca.2019.07.136_bib0036","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcin.2012.02.021","article-title":"Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism","volume":"5","author":"Agarwal","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1053\/j.jvca.2019.07.136_bib0037","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M17-2679","article-title":"Device closure versus medical therapy alone for patent foramen ovale in patients with cryptogenic stroke: A systematic review and meta-analysis","volume":"168","author":"Shah","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0038","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jacc.2005.10.044","article-title":"Patent foramen ovale: Innocent or guilty? Evidence from a prospective population-based study","volume":"47","author":"Meissner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.07.136_bib0039","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacc.2013.03.064","article-title":"Patent foramen ovale, subclinical cerebrovascular disease, and ischemic stroke in a population-based cohort","volume":"62","author":"Di Tullio","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2019.07.136_bib0040","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM198805053181802","article-title":"Prevalence of patent foramen ovale in patients with stroke","volume":"318","author":"Lechat","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0041","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0140-6736(88)92944-3","article-title":"Patent foramen ovale in young stroke patients","volume":"2","author":"Webster","year":"1988","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2019.07.136_bib0042","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1056\/NEJMoa071422","article-title":"Patent foramen ovale and cryptogenic stroke in older patients","volume":"357","author":"Handke","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0043","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-119-6-199309150-00003","article-title":"The prevalence of deep venous thrombosis in patients with suspected paradoxical embolism","volume":"119","author":"Stollberger","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0044","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/01.STR.24.1.31","article-title":"Patent foramen ovale: Is stroke due to paradoxical embolism?","volume":"24","author":"Ranoux","year":"1993","journal-title":"Stroke"},{"key":"10.1053\/j.jvca.2019.07.136_bib0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1161\/01.STR.0000106137.42649.AB","article-title":"Increased pelvic vein thrombi in cryptogenic stroke: Results of the Paradoxical Emboli from Large Veins in Ischemic Stroke (PELVIS) study","volume":"35","author":"Cramer","year":"2004","journal-title":"Stroke"},{"key":"10.1053\/j.jvca.2019.07.136_bib0046","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1161\/STROKEAHA.106.480863","article-title":"Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale","volume":"38","author":"Botto","year":"2007","journal-title":"Stroke"},{"key":"10.1053\/j.jvca.2019.07.136_bib0047","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2004-03-1107","article-title":"Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome","volume":"104","author":"de Laat","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.jvca.2019.07.136_bib0048","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/STROKEAHA.108.539171","article-title":"Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events: The PICSS-APASS study","volume":"40","author":"Rajamani","year":"2009","journal-title":"Stroke"},{"key":"10.1053\/j.jvca.2019.07.136_bib0049","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of 2 intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2019.07.136_bib0050","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.jvca.2019.07.136_bib0051","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): A randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.jvca.2019.07.136_bib0052","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1212\/WNL.0b013e3181aa2a19","article-title":"Recurrent cerebral ischemia in medically treated patent foramen ovale: A meta-analysis","volume":"73","author":"Almekhlafi","year":"2009","journal-title":"Neurology"},{"key":"10.1053\/j.jvca.2019.07.136_bib0053","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1161\/01.CIR.0000017498.88393.44","article-title":"Effect of medical treatment in stroke patients with patent foramen ovale: Patent foramen ovale in Cryptogenic Stroke Study","volume":"105","author":"Homma","year":"2002","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2019.07.136_bib0054","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1212\/WNL.0000000000002961","article-title":"Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"87","author":"Messe","year":"2016","journal-title":"Neurology"},{"key":"10.1053\/j.jvca.2019.07.136_bib0055","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1474-4422(18)30319-3","article-title":"Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: A prespecified subgroup analysis from the NAVIGATE ESUS trial","volume":"17","author":"Kasner","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.jvca.2019.07.136_bib0056","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source","volume":"380","author":"Diener","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077019307773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077019307773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T07:44:12Z","timestamp":1760946252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077019307773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1053077019307773"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2019.07.136","relation":{},"ISSN":["1053-0770"],"issn-type":[{"type":"print","value":"1053-0770"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Case-Based Discussion on the Management of Cryptogenic Stroke and Patent Foramen Ovale in the Patient With a Hypercoagulable Disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2019.07.136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}